Application of intravascular ultrasound in anti-atherosclerotic drug development

Nature Reviews Drug Discovery

Volumn 5, Issue 6, 2006, Pages 485-492

  Nicholls, Stephen J ^a   Sipahi, Ilke ^a   Schoenhagen, Paul ^a   Crowe, Tim ^a   Tuzcu, E Murat ^a   Nissen, Steven E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; ENALAPRIL; ETC 216; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PACTIMIBE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RIMONABANT; TORCETRAPIB; CARDIOVASCULAR AGENT;

ARTERY WALL; ATHEROMA; ATHEROSCLEROSIS; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG APPROVAL; DRUG DESIGN; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; HUMAN; INTRAVASCULAR ULTRASOUND; MORTALITY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE COURSE; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR AGENTS; CLINICAL TRIALS; DISEASE PROGRESSION; DRUG DESIGN; HUMANS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 33745933350     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2040     Document Type: Review

References (51)

1. Brown, M. S. & Goldstein, J. L. Heart attacks: Gone with the century? Science 272, 629 (1996).
2. Libby, P. The forgotten majority: Unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. 46, 1225-1228 (2005).
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
4. Pitt, B. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. 26, 1133-1139 (1995).
5. Jukema, J. W. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91, 2528-2540 (1995).
6. Blankenhorn, D. H. et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. 119, 969-976 (1993).
7. Arntz, H. R. et al. Beneficial effects of pravastatin (+/-colestyramine/ niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am. J. Cardiol. 86, 1293-1298 (2000).
8. Effect of simvastatin on coronary atheroma: The Multicentre Anti-Atheroma Study (MAAS). Lancet 344, 633-638 (1994).
9. Topol, E. J. & Nissen, S. E. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. Circulation 92, 2333-2342 (1995).
10. Glagov, S., Weisenberg, E., Zarins, C. K., Stankunavicius, R. & Kolettis, G. J. Compensatory enlargement of human atherosclerotic coronary arteries. N. Engl. J. Med. 316, 1371-1375 (1987).
11. Mintz, G. S. et al. Atherosclerosis in angiographically 'normal' coronary artery reference segments: An intravascular ultrasound study with clinical correlations. J. Am. Coll. Cardiol. 25, 1479-1485 (1995).
12. Schoenhagen, P., Ziada, K. M., Vince, D. G., Nissen, S. E. & Tuzcu, E. M. Arterial remodeling and coronary artery disease: The concept of 'dilated' versus 'obstructive' coronary atherosclerosis. J. Am. Coll. Cardiol. 38, 297-306 (2001).
13. Schoenhagen, P. et al. Association of arterial expansion (expansive remodeling) of bifurcation lesions determined by intravascular ultrasonography with unstable clinical presentation. Am. J. Cardiol. 88, 785-787 (2001).
14. Tuzcu, E. M. et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation 103, 2705-2710 (2001).
15. Nissen, S. E. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 291, 1071-1080 (2004).
16. Nissen, S. E. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 290, 2292-2300 (2003).
17. Nissen, S. E. etal. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 292, 2217-2225 (2004).
18. Mintz, G. S. et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J. Am. Coll. Cardiol. 37, 1478-1492 (2001).
19. Guedes, A. et al. Long-term safety of intravascular ultrasound in nontransplant, nonintervened, atherosclerotic coronary arteries. J. Am. Coll. Cardiol. 45, 559-564 (2005).
20. Ramasubbu, K. et al. Repeated intravascular ultrasound imaging in cardiac transplant recipients does not accelerate transplant coronary artery disease. J. Am. Coll. Cardiol. 41, 1739-1743 (2003).
21. Jensen, L. O., Thayssen, P., Pedersen, K. E., Stender, S. & Haghfelt, T. Regression of coronary atherosclerosis by simvastatin: A serial intravascular ultrasound study. Circulation 110, 265-270 (2004).
22. Okazaki, S. et al. Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation 110, 1061-1068 (2004).
23. Nissen, S. E. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352, 29-38 (2005).
24. Cannon, C. P. et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 350, 1495-1504 (2004).
25. Ridker, P. M. et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med. 352, 20-28 (2005).
26. Nissen, S. E. et al. Very high-intensity statin therapy and coronary atherosclerosis: The ASTEROID Trial JAMA 2006 Mar 13 [epub ahead of print].
27. Badimon, J. J., Badimon, L. & Fuster, V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J. Clin. Invest. 85, 1234-1241 (1990).
28. Chiesa, G. et al. Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ. Res. 90, 974-980 (2002).
29. Nicholls. S. J. et al. Reconstituted high density lipoproteins inhibit the acute pro-oxidant and proinflammatoryvascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111, 1543-1550 (2005).
30. Shah, P. K. et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Circulation 103, 3047-3050 (2001).
31. Brown, B. G. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583-1592 (2001).
32. Taylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K. & Grace, K. A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110, 3512-3517 (2004).
33. Nissen, S. E. et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med. 354, 1253-1263 (2006).
34. Dormandy, J. A. et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366, 1279-1289 (2005).
35. Tuzcu, E. M. et al. Intravascular ultrasound evidence of angiographically silent progression in coronary atheroscerosis predicts long-term morbidity and mortality after cardiac transplantation. J. Am. Coll. Cardiol. 45, 1538-1542 (2005).
36. Eisen, H. J. et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 349, 847-858 (2003).
37. Chambless, L. E. et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am. J. Epidemiol. 146, 483-494 (1997).
38. Hodis, H. N. et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann. Intern. Med. 128, 262-269 (1998).
39. Taylor, A. J. et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: A randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 106, 2055-2060 (2002).
40. Greenland, P., LaBree, L., Axen, S. P., Doherty, T. M. & Detrano, R. C. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 291, 210-215 (2004).
41. Achenbach, S. et al. Detection of coronary artery stenoses using multi-detector CT with 16×0.75 collimation and 375 ms rotation. Eur. Heart J. 26, 1978-1986 (2005).
42. Salm, L. P. et al. Comprehensive assessment of patients after coronary artery bypass grafting by 16-detector-row computed tomography. Am. Heart J. 150, 775-781 (2005).
43. Worthley, S. G. et al. Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. Circulation 101, 2956-2961 (2000).
44. Fayad, Z. A. et al. In vivo magnetic resonance evaluation of atherosclerotic plaques in the human thoracic aorta: A comparison with transesophageal echocardiography. Circulation 101, 2503-2509 (2000).
45. Corti, R. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: Two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 106, 2884-2887 (2002).
46. Lima, J. A. et al. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 110, 2336-2341 (2004).
47. Yonemura, A. et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J. Am. Coll. Cardiol. 45, 733-742 (2005).
48. Corti, R. et al. The selective peroxisomal proliferator-activated receptor-γ agonist has an additive effect on plaque regression in combination with simvastatin in experimental atherosclerosis: In vivo study by high-resolution magnetic resonance imaging. J. Am. Coll. Cardiol. 43, 464-473 (2004).
49. Worthley, S. G. et al. A novel nonobstructive intravascular MRI coil: In vivo imaging of experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 23, 346-350 (2003).
50. Nair, A. et al. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 106, 2200-2206 (2002).
51. Baldewsing, R. A. et al. Intravascular ultrasound elastography: A clinician's tool for assessing vulnerability and material composition of plaques. Stud. Health Technol. Inform. 113, 75-96 (2005).